Translational toxicology: a developmental focus for integrated research strategies

BMC Clinical Pharmacology

Iyabo Obasanjo³  David Allen¹  Michael Waters¹  Claude Hughes² 

[1] Integrated Laboratory Systems, Inc, Research Triangle Park, Durham, NC, USA;Quintiles, Inc, North Carolina State University; Wake Forest University; Duke University Medical Center, Morrisville, NC, USA;Advanced Leadership Fellow, Harvard University, Cambridge, MA, USA

关键词: Biomarkers;    Environmental health;    Translational toxicology;   

Others  :  860521
DOI  :  10.1186/2050-6511-14-51

 received in 2013-05-08, accepted in 2013-09-23,  发布年份 2013

【 摘 要 】

Background

Given that toxicology studies the potential adverse effects of environmental exposures on various forms of life and that clinical toxicology typically focuses on human health effects, what can and should the relatively new term of "translational toxicology" be taken to mean?

Discussion

Our assertion is that the core concept of translational toxicology must incorporate existing principles of toxicology and epidemiology, but be driven by the aim of developing safe and effective interventions beyond simple reduction or avoidance of exposure to prevent, mitigate or reverse adverse human health effects of exposures.

The field of toxicology has now reached a point where advances in multiple areas of biomedical research and information technologies empower us to make fundamental transitions in directly impacting human health. Translational toxicology must encompass four action elements as follows:

1) Assessing human exposures in critical windows across the lifespan

2) Defining modes of action and relevance of data from animal models

3) Use of mathematical models to develop plausible predictions as the basis for

4) Protective and restorative human health interventions.

The discussion focuses on the critical window of in-utero development.

Summary

Exposure assessment, basic toxicology and development of certain categories of mathematical models are not new areas of research; however overtly integrating these in order to conceive, assess and validate effective interventions to mitigate or reverse adverse effects of environmental exposures is our novel opportunity. This is what we should do in translational toxicology so that we have a portfolio of interventional options to improve human health that include both minimizing exposures and specific preventative/restorative/mitigative therapeutics.

【 授权许可】

   
2013 Hughes et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]McArdle H, Ashworth C: Micronutrients in fetal growth and development. Br Med Bull 1999, 55(3):499-510.
• [2]Radtke K, Ruf M, Gunter H, Dohrmann K, Schauer M, Meyer A, Elbert T: Transgenerational impact of intimate partner violence on methylation in the promoter of the glucocorticoid receptor. Translational Psychiatry 2011, 1 e21:1-6. doi:10.1038/tp.2011.21
• [3]Borghol N, Suderman M, McArdle W, Racine A, Hallett M, Pembrey M, Hertzman C, Power C, Szyf M: Associations with early-life socio-economic position in adult DNA methylation. Int J Epidemiol 2012, 41(1):62-74.
• [4]Tung J, Barreiroa L, Johnson Z, Hansenc K, Michopoulos V, Toufexis D, Michelinia K, Wilson M, Gilada Y: Social environment is associated with gene regulatory variation in the rhesus macaque immune system. PNAS 2012, 109:6490-6495.
• [5]Golden S, Robinson K, Saldanha I, Anton B, Ladenson P: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009, 94:1853-1878.
• [6]Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al.: The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011, 378(9793):804-814.
• [7]Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M: Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011, 378(9793):815-825.
• [8]Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP: Sympathetic nervous activation in obesity and the metabolic syndrome–causes, consequences and therapeutic implications. Pharmacol Ther 2010, 126(2):159-172.
• [9]Chouchane L, Danguir J, Beji C, Bouassida K, Camoin L, Sfar H, et al.: Genetic variation in the stress protein hsp70-2 gene is highly associated with obesity. Int J Obes Relat Metab Disord 2001, 25(4):462-466.
• [10]Birch L, Parker L, Burns A, Editors for the Committee on Obesity Prevention Policies for Young Children (Eds): Early Childhood Obesity Prevention Policies. Washington, DC: The National Academies Press; 2011.
• [11]Lloyd L, Langley-Evans S, McMullen S: Childhood obesity and risk of the adult metabolic syndrome: a systematic review. Int J Obes (Lond) 2012, 36:1-11.
• [12]Kirk SFL, Kuhle S, Ohinmaa A, Colman I, Veugelers , Paul J: Health care utilization from prevalent medical conditions in normal-weight, overweight, and obese children. J Pediatr 2012, 160:216-221.
• [13]Wang G, Dietz WH: Economic burden of obesity in youths aged 6 to 17 years: 1979–1999. Pediatrics 2002, 109(5):E81-81.
• [14]Ogden C, Carroll MD, Kit BK, Flegal KM: Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 2012, 307(5):483-490.
• [15]Salois MJ: The built environment and obesity among low-income preschool children. Health Place 2012, 18(3):520-527.
• [16]Guilloteau P, Zabielski R, Hammon HM, Metges CC: Adverse effects of nutritional programming during prenatal and early postnatal life, some aspects of regulation and potential prevention and treatments. J Physiol Pharmacol 2009, 60(Suppl 3):17-35.
• [17]Pryor J, Hughes C, Foster W, Hales B, Robaire B: Critical windows of exposure for children’s health: the reproductive system in animals and humans. Environ Health Perspect 2000, 108(Suppl 3):491-503.
• [18]Euling SY, Selevan SG, Pescovitz OH, Skakkebaek NE: Role of environmental factors in the timing of puberty. Pediatrics 2008, 121(Supplement 3):S167-S171. doi:10.1542/peds.2007-1813C
• [19]Fisch GS: Nosology and epidemiology in autism: classification counts. Am J Med Genet C Semin Med Genet 2012, 160C(2):91-103. doi:10.1002/ajmg.c.31325
• [20]Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M: Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309(16):1696-1703.
• [21]Benach JL, Li E, McGovern MM: A microbial association with autism. MBio 2012, 14(1):3. doi: 10.1128/mBio.00019-12
• [22]Becker KG: Male gender bias in autism and pediatric autoimmunity. Autism Res 2012, 5(2):77-83. doi:10.1002/aur.1227
• [23]Rai D, Lewis G, Lundberg M, Araya R, Svensson A, Dalman C, Carpenter P, Magnusson C: Parental socioeconomic status and risk of offspring autism spectrum disorders in a Swedish population-based study. J Am Acad Child Adolesc Psychiatry 2012, 51(5):467-476. e6. doi:10.1016/j.jaac.2012.02.012
• [24]Wang L, Leslie DL: Health care expenditures for children with autism spectrum disorders in Medicaid. J Am Acad Child Adolesc Psychiatry 2010, 49(11):1165-1171. doi:10.1016/j.jaac.2010.08.003
• [25]Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D, et al.: Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA 2013, 309(6):570-577.
• [26]Grimes D, Schulz K, Raymond E: Surrogate end points in women’s health research: science, protoscience, and pseudoscience. Fertil Steri l 2010, 93:1731-1734.
• [27]Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS: Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009, 16(1):50-59.
• [28]West P, Weir A, Smith A, Donley E, Cezar G: Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol 2010, 247:18-27.
• [29]Patti G, Yanes O, Siuzdak G: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012, 13:263-269.
• [30]Rottiers V, Näär A: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012, 13:239-250.
• [31]Kim J, Im J, Lee D: The relationship between leukocyte mitochondrial DNA contents and metabolic syndrome in postmenopausal women. Menopause 2012, 19(5):582-587.
• [32]Lemasters GK, Perreault SD, Hales BF, Hatch M, Hirshfield AN, Hughes CL, et al.: Workshop to identify critical windows of exposure for children’s health: Reproductive Health in Children and Adolescents Work Group summary. Environ Health Perspect 2000, 108(Suppl 3):505-509.
• [33]Holtcamp W: Obesogens: an environmental link to obesity. Environ Health Perspect 2012, 120(2):a62-a68.
• [34]Clausen T, Mathiesen E, Hansen T, Pedersen O, Jensen D, Lauenborg J, Schmidt L, Damm P: Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab 2009, 94:2464-2470.
• [35]Palou M, Priego T, Sanchez J, Torrens J, Palou A, Pico C: Moderate caloric restriction in lactating rats protects offspring against obesity and insulin resistance in later life. Endocrinology 2010, 151:1030-1041.
• [36]Hart R, Sloboda D, Doherty D, Norman R, Atkinson H, Newnham J, Dickinson J, Hickey M: Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antimullerian hormone in adolescence: a prospective cohort study. Fertil Steril 2010, 94:1544-1547.
• [37]Robertson DM, Hale GE, Fraser IS, Hughes CL, Burger HG: A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles. Menopause 2008, 15(6):1139-1144.
• [38]Gunatilake R, Patil AS: Drugs in pregnancy. In The Merck Manual for Health Care Professionals Online Edited by Porter RS, Kaplan JL. 2013, 1-9. http://www.merckmanuals.com/professional/gynecology_and_obstetrics/drugs_in_pregnancy/drugs_in_pregnancy.html webcite
• [39]Wilkes J, Clark L, Herrera J: Acetaminophen overdose in pregnancy. South Med J 2005, 98(11):1118-1122.
• [40]Rebordosa C, Kogevinas M, Horváth-Puhó E, Nørgård B, Morales M, Czeizel AE, Vilstrup H, Sørensen HT, Olsen J: Acetaminophen use during pregnancy: effects on risk for congenital abnormalities. Am J Obstet Gynecol 2008, 198(2):178.e1-178.e7.
• [41]Snijder C, Kortenkamp A, Steegers E, Jaddoe V, Hofman A, Hass U, Burdorf A: Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadia in the offspring. Hum Reprod 2012, 27(4):1191-1201.
• [42]Gedzelman E, Meador K: Antiepileptic drugs in women with epilepsy during pregnancy. Ther Adv in Drug Safe 2012, 3(2):71-87.
• [43]Johnson K, LaPrairie J, Brennan P, Stowe Z, Newport J: Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 2012, 69:787-794.
• [44]Daw J, Mintzes B, Law M, Hanley G, Morgan S: Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001–2006). Clin Ther 2012, 34:239-249.
• [45]Iqbal M, Sobhan T, Ryals T: Benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002, 53:39-49.
• [46]Nutrition Committee, Canadian Paediatric Society (CPS): Concerns for the use of soy-based formulas in infant nutrition. Paediatr Child Health 2009, 14(3):109-113.
• [47]TEDX (The Endocrine Disruption Exchange 2013): The TEDX list of potential endocrine disruptors. http://www.endocrinedisruption.org webcite
• [48]Frankenfeld C, Patterson R, Horner N, Neuhouser M, Skor H, Kalhorn T, Howald W, Lampe J: Validation of a soy food-frequency questionnaire and evaluation of correlates of plasma isoflavone concentrations in postmenopausal women. Am J Clin Nutr 2003, 77:674-680.
• [49]Engel S, Levy B, Liu Z, Kaplan D, Wolff M: Xenobiotic phenols in early pregnancy amniotic fluid. Reprod Toxicol 2006, 21:110-112.
• [50]Woodruff T, Zota A, Schwartz J: Environmental chemicals in pregnant women in the United States: NHANES 2003–2004. Environ Health Perspect 2011, 119:878-885. doi:10.1289/ehp.1002727
• [51]Wu C, Wang C, Kennedy J: Changes in herb and dietary supplement use in the US adult population: a comparison of the 2002 and 2007 National Health Interview Surveys. Clin Ther 2011, 2011(33):1749-1758.
• [52]La Maestra S, Kisby G, Micale R, Johnson J, Kow Y, Bao , Sheppard C, Stanfield S, Tran H, Woltjer R, D’Agostini F, Steele V, De Flora S: Cigarette smoke induces DNA damage and alters base-excision repair and Tau levels in the brain of neonatal mice. Toxicol Sci 2011, 123:471-479. doi:10.1093/toxsci/kfr187
• [53]Wang X, Tager I, Van Vunakis H, Speizer F, Hanrahan J: Maternal smoking during pregnancy, urine cotinine concentrations, and birth outcomes. a prospective cohort study. Int J Epidemiol 1997, 26:978-988. doi:10.1093/ije/26.5.978
• [54]El-Mohandes A, Kiely M, Gantz M, Blake S, El-Khorazaty M: Prediction of birth weight By cotinine levels during pregnancy in a population of black smokers. Pediatrics 2009, 124:e671-e680.
• [55]Dietz P, Homa D, England L, Burley K, Tong V, Dube S, Bernert J: Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of reproductive age in the United States. Am J Epidemiol 2011, 173:355-359. doi:10.1093/aje/kwq381
• [56]Wright T, Milam K, Rougee L, Tanaka M, Collier A: Agreement of umbilical cord drug and cotinine levels with maternal self-report of drug use and smoking during pregnancy. J Perinatol 2011, 31:324-329. doi:10.1038/jp.2010.132
• [57]Centers for Diseases Control: Tobacco use and pregnancy. 2013. http://www.cdc.gov/reproductivehealth/tobaccousepregnancy/ webcite
• [58]American College of Obstetricians and Gynecologists: At-risk drinking and alcohol dependence: obstetric and gynecologic implications. Committee Opinion 2011, 496:1-6.
• [59]Tracy E: Alcohol: an unfortunate teratogen. OBG Management 2013, 25:37-45.
• [60]NIDA: Topics in brief: prenatal exposure to drugs of abuse, a research update from the National Institute on Drug Abuse. 2011. http://www.drugabuse.gov webcite
• [61]Gouzoulis-Mayfrank E, Daumann J: Neurotoxicity of drugs of abuse - the case of methylenedioxyamphetamines (MDMA, ecstacy), and amphetamines. Dialogues Clin Neurosci 2009, 11(3):305-317.
• [62]Alexander SPH, Mathie A, Peters JA: Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 2011, 164(Suppl. 1):S1-S324.
• [63]Vandenberg L, Colborn T, Hayes T, Heindel J, Jacobs D, Lee D, Shioda T, Soto A, vom Saal F, Welshons W, Zoeller R, Myers J: Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev 2012, 33:378-455.
• [64]Birnbaum L: Environmental chemicals: evaluating low-dose effects. Environ Health Perspect 2012, 120:A143-144. doi:10.1289/ehp.1205179
• [65]Ali H, Al-Mulla F: Defining umbilical cord blood stem cells. Stem Cell Discovery 2012, 2:15-23. doi:10.4236/scd.2012.21003
• [66]Lapid K, Chen Glait-Santar C, Shiri Gur-Cohen S, Canaani J, Kollet O, Lapidot T: Egress and mobilization of hematopoietic stem and progenitor cells: a dynamic multi-facet process. In Stem Book Edited by Melton D, Girard L. 2013, 1940-3429. http://www.stembook.org/node/762 webcite
• [67]Messner H: Stem cells: the challenge and opportunities. Bone Marrow Transplant 2008, 42(Suppl 1):S57-S59.
• [68]Kavanagh DP, Durant LE, Crosby HA, Lalor PF, Frampton J, Adams DH, et al.: Haematopoietic stem cell recruitment to injured murine liver sinusoids depends on (alpha)4(beta)1 integrin/VCAM-1 interactions. Gut 2010, 59:79-87.
• [69]Broad Institute: "The Connectivity Map.". 2012. http://www.broadinstitute.org/cmap/ webcite
• [70]Feng H, Cheng AS, Tsang DP, Li MS, Go MY, Cheung YS, et al.: Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest 2011, 121:3159-3175.
• [71]Reamon-Buettner S, Mutschler V, Borlak J: The next innovation cycle in toxicogenomics: environmental epigenetics. Mutat Res 2008, 659:158-165.
• [72]Ng S, Lin R, Laybutt D, Barres R, Owens J, Morris M: Chronic high-fat diet in fathers programs b-cell dysfunction in female rat offspring. Nature 2010, 96:963-967.
• [73]Mathers JC, Strathdee G, Relton CL: Induction of epigenetic alterations by dietary and other environmental factors. Adv Genet 2010, 71:3-39.
• [74]Jousse C, Parry L, Lambert-Langlais S, Maurin AC, Averous J, Bruhat A, Carraro V, Tost J, Letteron P, Chen P, Jockers R, Launay JM, Mallet J, Fafournoux P: Perinatal undernutrition affects the methylation and expression of the leptin gene in adults: implication for the understanding of metabolic syndrome. FASEB J 2011, 25:3271-3278.
• [75]Kooistra S, Helin K: Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012, 13:297-311. doi:10.1038/nrm3327
• [76]Hanover JA, Krause MW, Love DC: Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 2012, 13:312-321. doi:10.1038/nrm3334
• [77]Bell J, Tsai P, Yang T, Pidsley R, Nisbet J, Glass D, Mangino M, Zhai G, Zhang F, Valdes A, Shin S, Dempster E, Murray R, Grundberg E, Hedman A, Nica A, Small K, Dermitzakis E, McCarthy M, Mill J, Spector T, Deloukas P, The MuTHER Consortium: Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet 2012, 8(4):e1002629:1-e1002629:12.
• [78]Siddique J, Lantos J, VanderWeele T, Lauderdale D: Screening tests during prenatal care: does practice follow the evidence? Matern Child Health J 2012, 16:51-59.
• [79]Pauli JM, Repke JT: Update: obstetrics. OBG Management 2013, 25:28-31.
• [80]American Academy of Pediatrics Committee on Genetics: Folic acid for the prevention of neural tube defects. Pediatrics 1999, 104:325-327.
• [81]U.S. Preventive Services Task Force: Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 150:626-631.
• [82]Koletzko B, Lien E, Agostoni C, Böhles H, Campoy C, Cetin I, Decsi T, Dudenhausen JW, Dupont C, Forsyth S, Hoesli I, Holzgreve W, Lapillonne A, Putet G, Secher NJ, Symonds M, Szajewska H, Willatts P, Uauy R, World Association of Perinatal Medicine Dietary Guidelines Working Group: The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 2008, 36:5-14.
• [83]Coleman T, Cooper S, Thornton J, Grainge M, Watts K, Britton J, Lewis S, for the Smoking, Nicotine, and Pregnancy (SNAP) Trial Team: A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med 2012, 366:808-818.
• [84]De Flora S, Izzotti A, D’Agostini F, Balansky R: Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 2001, 22:999-1013.
• [85]Van Schooten F, Nia A, De Flora S, D’Agostini F, Izzotti A, Camoirano A, Balm A, Dallinga J, Bast A, Haenen G, Van’t Veer L, Baas P, Sakai H, Van Zandwijk N: Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev 2002, 11:167-175.
• [86]Abalovich M, Amino N, Barbour L, Cobin R, De Groot L, Glinoer D, Mandel S, Stagnaro-Green A: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2007, 92(Suppl):S1-S47.
• [87]Rivkees S, Mandel S: Thyroid disease in pregnancy. Horm Res Paediatr 2011, 76(Suppl. 1):91-96.
• [88]Shields B, Knight B, Hill A, Hattersley A, Vaidya B: Fetal thyroid hormone level at birth is associated with fetal growth. J Clin Endocrinol Metab 2011, 96(6):E934-E938.
• [89]Kuppens S, Kooistra L, Wijnen H, Vader H, Hasaart T, Oei S, Vulsma T, Pop V: Neonatal thyroid screening results are related to gestational maternal thyroid function. Clin Endocrinol (Oxf) 2011, 75:382-387.
• [90]Lazarus J, Bestwick J, Channon S, Paradice R, Maina A, Rees R, Chiusano E, John R, Guaraldo V, George L, Perona M, Dall’Amico D, Parkes A, Joomun M, Wald N: Antenatal thyroid screening and childhood cognitive function. N Engl J Med 2012, 366:493-501.
• [91]Nelson K, Grether J: Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995, 95:263-269.
• [92]Rouse D, Hirtz D, Thom E, Varner M, Spong C, Mercer B, Iams J, Wapner R, Sorokin Y, Alexander J, Harper M, Thorp J, Ramin S, Malone F, Carpenter M, Miodovnik M, Moawad A, O’Sullivan M, Peaceman A, Hankins G, Langer O, Caritis S, Roberts J, for the Eunice Kennedy Shriver NICHD Maternal–Fetal Medicine Units Network: A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008, 359:895-905.
• [93]Conde-Agudelo A, Romero R: Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks’ gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009, 595-609. doi:10.1016/j.ajog.2009.04.005 June 2009
• [94]Rouse D: Magnesium sulfate for the prevention of cerebral palsy. Am J Obstet Gynecol 2009, 2009(200):610-612. doi:10.1016/j.ajog.2009.04.004
• [95]Doyle L, Crowther C, Middleton P, Marret S: Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol 2009, 113:1327-1333.
• [96]Ibanez L, Lopez-Bermejo A, Diaz M, Marcos MV, De Zegher F: Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil Steril 2011, 95:727-730.
• [97]Ibanez L, Lopez-Bermejo A, Diaz M, Marcos MV, De Zegher F: Early metformin therapy (age 8–12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab 2011, 96:E1262-E1267.
• [98]U.S. Enviromental Protection Agency: Endocrine Disruptor Screening Program. 2013. http://www.epa.gov/endo/pubs/edspoverview/edstac.htm webcite
• [99]Van Ravenzwaay B, Coelho-Palermo Cunha G, Leibold E, Looser R, Mellert W, Prokoudine A, Walk T, Wiemer J: The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 2007, 172:21-28.
• [100]Robertson DG, Watkins PB, Reily MD: Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci 2011, 120(Suppl 1):S146-S170. doi:10.1093/toxsci/kfq358